China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its HDM1005, a long-acting GLP-1/GIP receptor agonist, has received clinical trial approval from the National Medical Products Administration (NMPA) for obstructive sleep apnea (OSA) combined with obesity or overweight. The drug previously received nods for type 2 diabetes, weight loss, and metabolic fatty liver disease in China.
Drug Profile
HDM1005 activates GLP-1 and GIP receptors, promoting insulin release and appetite suppression. Preclinical studies demonstrated significant effects on glucose tolerance, blood sugar reduction, and weight loss. The molecule showed favorable pharmacokinetic properties and safety in early research.-Fineline Info & Tech
Leave a Reply